Pharmaceutical Distribution: approx. 70%
Medical Devices: approx. 20%
Health Products: approx. 10%

TOP 3 Markets:

1. China: approx. 85%
2. Southeast Asia: approx. 10%
3. Africa: approx. 5%

Jointown Pharmaceutical Group Co., Ltd generates the majority of its revenue from pharmaceutical distribution, which is typical for companies in this sector. The domestic market China dominates the revenue distribution, attributed to its strong market presence and comprehensive distribution network within the country. Southeast Asia and Africa are emerging markets gaining importance through strategic expansions and partnerships.

Production Sites: China (Headquarters in Wuhan)

Jointown Pharmaceutical Group Co., Ltd is headquartered in Wuhan, China, and also operates the majority of its production facilities there. The company is one of the largest pharmaceutical wholesalers in China, focusing on the manufacturing and distribution of pharmaceutical products and medical devices.

In addition to the production sites in Wuhan, Jointown has an extensive network of logistics centers and distribution branches throughout China to ensure efficient market supply.

Revenue Growth: Estimated 10% annually (2025) Market Expansion: Focus on international markets

Jointown Pharmaceutical Group Co., Ltd is pursuing a strategy that focuses on diversified growth paths. The company plans to increase its revenue growth by tapping into new international markets. This includes expanding its presence in Asia and exploring opportunities in Europe and North America.

In addition, Jointown is investing in digitizing its supply chain to achieve efficiency gains and increase customer satisfaction. By leveraging technology, the company aims to enhance its operational efficiency while reducing costs.

Another strategic focus is on expanding the product portfolio, particularly in the generics and health products sector, to meet the changing needs of consumers. This is intended to be achieved through targeted acquisitions and partnerships.

Main Imported Raw Materials: Active Pharmaceutical Ingredients (APIs), Packaging Materials

Countries of Origin: India, China, Germany

Jointown Pharmaceutical Group Co., Ltd mainly imports active pharmaceutical ingredients (APIs) that are essential for the production of medications. India is one of the largest suppliers of these ingredients, as the country is a significant producer of APIs.

In addition, the company imports packaging materials necessary for the safe and effective distribution of medications. These materials often come from Germany, which is known for its high-quality packaging solutions.

China itself is also an important supplier, especially for raw materials that are locally produced and needed for further processing in the pharmaceutical industry.

Market share: 7.5% (estimated 2025)
Revenue growth: 10.2% (2024)
Gross margin: 18.5% (2024)

Jointown Pharmaceutical Group Co., Ltd. has established itself as one of the leading pharmaceutical wholesalers in China. With an estimated market share of 7.5% in 2025, the company demonstrates a strong presence in the Chinese market, attributed to its extensive distribution infrastructure and its ability to offer a wide range of products.

The revenue growth of 10.2% in 2024 indicates that the company is able to further strengthen its market position and benefit from the growing demand in the healthcare sector. The gross margin of 18.5% shows that Jointown is capable of managing its costs efficiently while offering competitive prices.

Jointown's competitive advantage lies in its comprehensive logistics and distribution infrastructure, enabling the company to operate efficiently and cost-effectively. Additionally, Jointown benefits from strategic partnerships and a broad product portfolio, allowing it to flexibly respond to market changes.

Institutional Investor Share: Estimated at 45% (2025)
Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Jointown Pharmaceutical Group Co., Ltd is approximately 45%. This demonstrates the confidence of institutional investors in the company and its long-term growth prospects.

In 2025, there were no significant insider buys or sells, indicating that the management and other insiders are currently not making any significant changes to their stake in the company. This can be interpreted as a sign of stability and confidence in the current corporate strategy.

Market share of Jointown Pharmaceutical Group Co., Ltd: Estimated 8% (2025)

Main competitors and their market shares:

1. Sinopharm Group Co., Ltd: 20%
2. Shanghai Pharmaceuticals Holding Co., Ltd: 15%
3. China Resources Pharmaceutical Group Ltd: 12%
4. Jointown Pharmaceutical Group Co., Ltd: 8%
5. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd: 7%

Moat Analysis:

Jointown Pharmaceutical Group Co., Ltd has a moderate moat, mainly characterized by its broad distribution infrastructure and strong regional presence. The company has invested in digitization and efficiency improvement of its supply chains in recent years, giving it a certain advantage.

In comparison to competitors, Sinopharm has the strongest moat, due to its market leadership, comprehensive product range, and strong connections to government health projects. Shanghai Pharmaceuticals and China Resources Pharmaceutical also benefit from strong networks and diversified business models.

Overall, Jointown has a significant, but not dominant moat. The competition generally has better defense mechanisms due to larger market shares and stronger strategic alliances.

Revenue Growth: 8.5% (2024) Profit Growth: 7.2% (2024) Market Share in China: 5.8% (2024)

Jointown Pharmaceutical Group Co., Ltd recorded a revenue growth of 8.5% in 2024, attributed to solid demand in the pharmaceutical sector and an effective distribution strategy. The company has further strengthened its market position in China, holding a market share of 5.8%, making it one of the leading players in the Chinese pharmaceutical market.

The profit growth of 7.2% during the same period indicates that Jointown is able to effectively manage its costs and remain profitable. This is particularly important in a competitive market environment where margins are often under pressure.

Overall, the stable financial performance and strong market position suggest that Jointown Pharmaceutical Group Co., Ltd is a solid investment, especially for investors interested in long-term growth in the pharmaceutical sector. However, it is advisable to also consider external factors such as regulatory changes and market trends before making a final investment decision.

Dividend Yield: 2.5% (estimated for 2025)
Dividend History: Regular payouts over the last 5 years

Jointown Pharmaceutical Group Co., Ltd has regularly distributed dividends to its shareholders in recent years. The company's dividend policy shows a certain reliability, as there have been no missed payouts in the last five years.

The estimated dividend yield for 2025 is around 2.5%, which can be considered moderate compared to other companies in the industry. This stability in dividend policy indicates that Jointown aims to provide its shareholders with continuous returns, although the exact amount of the dividend may vary from year to year depending on financial results and the overall market situation.